VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 355 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2013. The put-call ratio across all filers is 0.61 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $449,000 | -23.2% | 22,319 | 0.0% | 0.02% | -21.1% |
| Q1 2016 | $585,000 | -77.2% | 22,319 | -12.9% | 0.02% | -78.7% |
| Q4 2015 | $2,564,000 | -40.3% | 25,639 | +6.7% | 0.09% | -35.0% |
| Q3 2015 | $4,293,000 | -12.3% | 24,024 | +9.1% | 0.14% | -10.5% |
| Q2 2015 | $4,894,000 | +69.8% | 22,020 | +50.8% | 0.15% | +70.0% |
| Q1 2015 | $2,882,000 | +37.9% | 14,603 | +0.1% | 0.09% | +45.2% |
| Q4 2014 | $2,090,000 | +12.8% | 14,592 | +12.0% | 0.06% | +264.7% |
| Q3 2014 | $1,853,000 | +12.5% | 13,028 | 0.0% | 0.02% | -67.3% |
| Q2 2014 | $1,647,000 | +7.0% | 13,028 | +11.4% | 0.05% | 0.0% |
| Q1 2014 | $1,539,000 | +14.7% | 11,700 | +8.7% | 0.05% | +10.6% |
| Q4 2013 | $1,342,000 | -20.5% | 10,766 | -33.5% | 0.05% | -27.7% |
| Q3 2013 | $1,688,000 | +196.1% | 16,182 | +144.7% | 0.06% | +195.5% |
| Q2 2013 | $570,000 | – | 6,613 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,586,582 | $864,160,000 | 32.02% |
| FARLEY CAPITAL L.P. | 341,518 | $44,807,000 | 30.12% |
| LeVasseur Capital Partners LLC | 190,404 | $24,981,000 | 29.94% |
| Ruane, Cunniff & Goldfarb | 34,494,015 | $4,525,615,000 | 23.97% |
| ValueAct Holdings | 18,923,877 | $2,482,813,000 | 16.64% |
| White River Investment Partners, LLC | 90,099 | $11,820,000 | 16.35% |
| Tesuji Partners | 1,368,040 | $179,487,000 | 15.45% |
| Arrow Capital Management, LLC | 197,500 | $25,912,000 | 15.11% |
| Hound Partners | 3,576,998 | $469,302,000 | 14.87% |
| Brahman Capital Corp. | 4,457,153 | $584,778,000 | 12.82% |